PVR and acute myeloid leukemia: Importantly, therapeutic blockade of the CD155-TIGIT axis with anti-TIGIT antibodies markedly promoted NK cell–mediated killing of TP53/TET2 comutant AML cells and extended survival in mice engrafted with Tp53/Tet2 double-KO AML cells.